Lilly opens broader early-access program for unapproved obesity drug retatrutide

Eli Lilly said on Monday that it will allow more patients to apply for early access to retatrutide, an experimental obesity drug that has not been approved by U.S. regulators ^[1][2]. The decision came six weeks after the company gave the drug to a single 79-year-old patient through a special access arrangement ^[1].

"For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance," a Lilly spokesperson said ^[1][2]. Lilly said it has built an expanded access program that does that and is actively reviewing requests from health care providers ^[1][2].

The eligibility rules Lilly described are narrow. Patients must be 18 or older. They must have obesity that has not responded to treatment even though they tolerated the highest approved dose of an obesity therapy, and they must have at least two serious or life-threatening obesity-related complications for which they are receiving care. They also must be unable to take part in an ongoing clinical trial of retatrutide or a comparable investigational treatment ^[2].

Retatrutide is designed to target three metabolic hormones: GLP-1, GIP and glucagon. Lilly's current injectable obesity drug, Zepbound, targets GLP-1 and GIP ^[2]. Lilly said in July that an 80-week trial in adults with severe obesity and established heart disease showed average weight loss of 22.6% at the highest weekly dose ^[2]. The company plans to file for approval of retatrutide with the FDA in the first quarter of next year ^[2].

Doctors had been asking Lilly for the same kind of access for their own patients. STAT, which first reported the single compassionate-use case in June, then asked the company about requests from a handful of physicians that had gone unanswered; Lilly confirmed the broader program the same day ^[1][2]. The move drew objections from some physicians, who said expanded access for an obesity drug sets a difficult precedent ^[1].

Why it matters for patients

For people with severe obesity who have already tried approved treatments at the highest dose they can tolerate, the program creates a route to a drug that is otherwise available only inside a clinical trial ^[2]. The criteria are strict, though. Patients need at least two serious or life-threatening obesity-related complications and must already be receiving care for them, and they cannot have a trial open to them ^[2].

That means this is not a general early-access path for anyone who wants to try a newer weight-loss medicine. Retatrutide is still unapproved, and Lilly has said it intends to seek FDA approval in early 2027 ^[1][2]. Lilly has not disclosed how many patients it will accept, what it will charge for the drug under the program, or how quickly requests will be reviewed.

What happens next

Lilly said it is reviewing requests from health care providers now ^[1][2]. The company plans to file for FDA approval of retatrutide in the first quarter of 2027 ^[2]. Whether Lilly will publish the number of patients accepted into the program, or its terms, has not been disclosed.